Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - aripiprazole, quantity: 5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; indigo carmine aluminium lake; microcrystalline cellulose; lactose monohydrate; hyprolose; colloidal anhydrous silica; maize starch - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - aripiprazole, quantity: 5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; indigo carmine aluminium lake; hyprolose; magnesium stearate; microcrystalline cellulose; maize starch - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - aripiprazole, quantity: 30 mg - tablet, uncoated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; lactose monohydrate; hyprolose; maize starch - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - aripiprazole, quantity: 2 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; iron oxide yellow; maize starch; microcrystalline cellulose; hyprolose; indigo carmine aluminium lake; colloidal anhydrous silica - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - aripiprazole, quantity: 30 mg - tablet, uncoated - excipient ingredients: maize starch; colloidal anhydrous silica; magnesium stearate; lactose monohydrate; microcrystalline cellulose; hyprolose - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

physicians total care, inc. - estropipate (unii: svi38uy019) (estropipate - unii:svi38uy019) - estropipate 0.75 mg - estropipate tablets are indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause. treatment of moderate to severe vasomotor symptoms associated with the menopause. - treatment of moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. treatment of moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. - prevention of postmenopausal osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be con

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

hospira, inc - piperacillin sodium (unii: m98t69q7hp) (piperacillin anhydrous - unii:9i628532gx), tazobactam sodium (unii: uxa545abtt) (tazobactam - unii:se10g96m8w) - piperacillin anhydrous 2 g in 10 ml - piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of escherichia coli or the following members of the bacteroides fragilis group: b. fragilis, b. ovatus, b. thetaiotaomicron , or b. vulgatus . piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of staphylococcus aureus and by piperacillin and tazobactam-susceptible acinetobacter baumannii, haemophilus influenzae, klebsiella pneumoniae, and pseudomonas aeruginosa (nosocomial pneumonia caused by p. aeruginosa should be treated in combination with an aminoglycoside) [see dosage and administration (2)]. piperacillin and tazobactam for injection is indicated in adults for the treatment of uncomplic

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

hospira, inc - piperacillin sodium (unii: m98t69q7hp) (piperacillin anhydrous - unii:9i628532gx), tazobactam sodium (unii: uxa545abtt) (tazobactam - unii:se10g96m8w) - piperacillin anhydrous 2 g - piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of escherichia coli or the following members of the bacteroides fragilis group: b. fragilis, b. ovatus, b. thetaiotaomicron , or b. vulgatus . piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of staphylococcus aureus and by piperacillin and tazobactam-susceptible acinetobacter baumannii, haemophilus influenzae, klebsiella pneumoniae, and pseudomonas aeruginosa (nosocomial pneumonia caused by p. aeruginosa should be treated in combination with an aminoglycoside) [see dosage and administration (2) ]. piperacillin and tazobactam for injection is indicated in adults for the treatment of uncompli

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

sandoz inc - piperacillin sodium (unii: m98t69q7hp) (piperacillin anhydrous - unii:9i628532gx), tazobactam sodium (unii: uxa545abtt) (tazobactam - unii:se10g96m8w) - piperacillin anhydrous 2 g in 10 ml - piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of escherichia coli or the following members of the bacteroides fragilis group: b. fragilis , b. ovatus , b. thetaiotaomicron , or b. vulgatus . piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of staphylococcus aureus and by piperacillin and tazobactam-susceptible acinetobacter baumannii, haemophilus influenzae, klebsiella pneumoniae, and pseudomonas aeruginosa (nosocomial pneumonia caused by p. aeruginosa should be treated in combination with an aminoglycoside) [see dosage and administration (2)] . piperacillin and tazobactam for injection is indicated in adults for the treatment of uncompl

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

hospira, inc - piperacillin sodium (unii: m98t69q7hp) (piperacillin anhydrous - unii:9i628532gx), tazobactam sodium (unii: uxa545abtt) (tazobactam - unii:se10g96m8w) - piperacillin anhydrous 12 g in 60 ml - piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of escherichia coli or the following members of the bacteroides fragilis group: b. fragilis, b. ovatus, b. thetaiotaomicron , or b. vulgatus . piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of staphylococcus aureus and by piperacillin and tazobactam-susceptible acinetobacter baumannii, haemophilus influenzae, klebsiella pneumoniae , and pseudomonas aeruginosa (nosocomial pneumonia caused by p. aeruginosa should be treated in combination with an aminoglycoside) [see dosage and administration (2) ]. piperacillin and tazobactam for injection is indicated in adults for the treatment of uncompli